

**Acknowledgment and Consent for Disclosure of  
Section 712(c)(2)(B) of the Federal Food, Drug, and Cosmetic Act  
and 18 U.S.C. §208  
Particular Matter Waivers**

Name: James C. Eisenach, M.D.

Committee: Anesthetic and Life Support Drugs Advisory Committee

Meeting Date(s): March 11, 2008

I acknowledge that contingent upon public disclosure of the following financial interest submitted on my FDA Form 3410 and related to the agenda item: to discuss new drug application NDA 22-225, sugammadex sodium injection (Org25969) proposed trade name Bridion, sponsored by Organon USA, a subsidiary of Schering-Plough Corporation, proposed indication of routine reversal of shallow and profound neuromuscular blockade (NMB) induced by rocuronium or vecuronium and immediate reversal of NMB at 3 minutes after administration of rocuronium, I am eligible to receive particular matter waivers under Section 712(c)(2)(B) and 18 U.S.C. §208.

<b>Type of Interest</b>	<b>Involvement</b>	<b>Magnitude</b>
Unrelated Consulting	Sponsor	Less than \$10,001 per year

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading the statement into the record at the time of the meeting. I understand that without public disclosure of the interest, the waivers are not valid.

\_\_\_\_\_/S/\_\_\_\_\_  
Signature

\_\_\_\_\_/1/30/08\_\_\_\_\_  
Date